title: Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation.
abstract: OBJECTIVE
  To look for factors predictive of acute urinary retention (AUR) after permanent seed prostate brachytherapy.
  
  
  METHODS
  From March 1999 to February 2001, 150 permanent seed prostate implants were performed at Princess Margaret Hospital (Stage T1c, n = 113; T2a, n = 37; mean prostate-specific antigen level 5.9 ng/mL, prescription dose 145 Gy per Task Group No. 43). alpha-Blockers were used routinely after implantation. Dosimetry was based on the 1-month postimplant CT scan. The International Prostate Symptom Score (IPSS) and catheterization were recorded at 1 month and 3 months and then every 3 months. The following variables were examined: age, baseline IPSS, prior androgen ablation, prostate transrectal ultrasound volume, number of seeds, D(90), V(100), V(200), and urethral dose.
  
  
  RESULTS
  Twenty patients (13%) experienced AUR. No difference was seen in the mean D(90) (149 Gy vs. 152 Gy, p = 0.6), V(100) (90% vs. 91%, p = 0.6), V(200) (23% vs. 25% p = 0.4), IPSS (6.4 vs. 5.9, p = 0.8), or maximal urethral dose (204 Gy vs. 210 Gy, p = 0.5). The prostate volume was significantly larger in men with AUR (39.8 cm(3) vs. 34.3 cm(3), p = 0.003), and the mean number of seeds was higher (112 vs. 103, p = 0.006). Of the 20 patients experiencing AUR, 11 (55%) had received prior antiandrogen therapy to downsize their prostates vs. 35 (27%) of the 130 who did not have AUR (p = 0.02). Multivariate analysis showed prostate volume and prior hormone use to be independent predictors of AUR.
  
  
  CONCLUSIONS
  Implant quality as determined by D(90), V(100), V(200), and urethral dose did not predict AUR. Prostate size was the major determinant of AUR. For any given prostate size, prior androgen ablation increased the risk of AUR. Men with larger prostates should be aware of the increased risk when contemplating brachytherapy.
authors.affiliation: Department of Radiation Oncology, University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada.
authors.forename: Juanita
authors.initials: J
authors.lastname: Crook
authors.forename: Michael
authors.initials: M
authors.lastname: McLean
authors.forename: Charles
authors.initials: C
authors.lastname: Catton
authors.forename: Ivan
authors.initials: I
authors.lastname: Yeung
authors.forename: John
authors.initials: J
authors.lastname: Tsihlias
authors.forename: Melania
authors.initials: M
authors.lastname: Pintilie
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D001918:Brachytherapy / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D012044:Regression Analysis; D018084:Ultrasonography, Interventional / Q000379:methods; D016055:Urinary Retention / Q000209:etiology*
chemical_list: D000726:Androgen Antagonists